BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37032230)

  • 21. Epigenetic Modifications and Modulators in Prostate Cancer.
    Cimadamore A; Gasparrini S; Scarpelli M; Doria A; Mazzucchelli R; Massari F; Cheng L; Lopez-Beltran A; Montironi R
    Crit Rev Oncog; 2017; 22(5-6):439-450. PubMed ID: 29604923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic alterations in human prostate cancers.
    Nelson WG; De Marzo AM; Yegnasubramanian S
    Endocrinology; 2009 Sep; 150(9):3991-4002. PubMed ID: 19520778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic regulation of prostate cancer: the theories and the clinical implications.
    Liao Y; Xu K
    Asian J Androl; 2019; 21(3):279-290. PubMed ID: 30084432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic modifications in prostate cancer.
    Sugiura M; Sato H; Kanesaka M; Imamura Y; Sakamoto S; Ichikawa T; Kaneda A
    Int J Urol; 2021 Feb; 28(2):140-149. PubMed ID: 33111429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenomics in stress tolerance of plants under the climate change.
    Kumar M; Rani K
    Mol Biol Rep; 2023 Jul; 50(7):6201-6216. PubMed ID: 37294468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.
    Babbio F; Pistore C; Curti L; Castiglioni I; Kunderfranco P; Brino L; Oudet P; Seiler R; Thalman GN; Roggero E; Sarti M; Pinton S; Mello-Grand M; Chiorino G; Catapano CV; Carbone GM; Bonapace IM
    Oncogene; 2012 Nov; 31(46):4878-87. PubMed ID: 22330138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EZH2, an epigenetic driver of prostate cancer.
    Yang YA; Yu J
    Protein Cell; 2013 May; 4(5):331-41. PubMed ID: 23636686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer.
    Toiyama Y; Okugawa Y; Goel A
    Biochem Biophys Res Commun; 2014 Dec; 455(1-2):43-57. PubMed ID: 25128828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic DNA methylation markers for prostate cancer.
    Strand SH; Orntoft TF; Sorensen KD
    Int J Mol Sci; 2014 Sep; 15(9):16544-76. PubMed ID: 25238417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic regulation of the ITGB4 gene in prostate cancer.
    Wilkinson EJ; Woodworth AM; Parker M; Phillips JL; Malley RC; Dickinson JL; Holloway AF
    Exp Cell Res; 2020 Jul; 392(2):112055. PubMed ID: 32376286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer.
    Kurfurstova D; Bartkova J; Vrtel R; Mickova A; Burdova A; Majera D; Mistrik M; Kral M; Santer FR; Bouchal J; Bartek J
    Mol Oncol; 2016 Jun; 10(6):879-94. PubMed ID: 26987799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deregulation of an imprinted gene network in prostate cancer.
    Ribarska T; Goering W; Droop J; Bastian KM; Ingenwerth M; Schulz WA
    Epigenetics; 2014 May; 9(5):704-17. PubMed ID: 24513574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urinary biomarkers in prostate cancer detection and monitoring progression.
    Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
    Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global and region-specific post-transcriptional and post-translational modifications of bisphenol A in human prostate cancer cells.
    Fatma Karaman E; Caglayan M; Sancar-Bas S; Ozal-Coskun C; Arda-Pirincci P; Ozden S
    Environ Pollut; 2019 Dec; 255(Pt 2):113318. PubMed ID: 31610501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer epigenetics and its clinical implications.
    Yegnasubramanian S
    Asian J Androl; 2016; 18(4):549-58. PubMed ID: 27212125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.
    Börno ST; Fischer A; Kerick M; Fälth M; Laible M; Brase JC; Kuner R; Dahl A; Grimm C; Sayanjali B; Isau M; Röhr C; Wunderlich A; Timmermann B; Claus R; Plass C; Graefen M; Simon R; Demichelis F; Rubin MA; Sauter G; Schlomm T; Sültmann H; Lehrach H; Schweiger MR
    Cancer Discov; 2012 Nov; 2(11):1024-35. PubMed ID: 22930729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feedback networks between microRNAs and epigenetic modifications in urological tumors.
    Liep J; Rabien A; Jung K
    Epigenetics; 2012 Apr; 7(4):315-25. PubMed ID: 22414795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of RASSF1 promoter methylation in prostate cancer.
    Daniunaite K; Jarmalaite S; Kalinauskaite N; Petroska D; Laurinavicius A; Lazutka JR; Jankevicius F
    J Urol; 2014 Dec; 192(6):1849-55. PubMed ID: 24980613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
    Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
    Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA epigenetic signatures in human disease.
    Piletič K; Kunej T
    Arch Toxicol; 2016 Oct; 90(10):2405-19. PubMed ID: 27557899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.